Cowen analyst Charles Ryhee lowered the firm’s price target on Amwell to $5 from $9 and keeps an Outperform rating on the shares. The analyst said we believe 2023 guidance is built on conservative assumptions with minimal CVS, which could lead to potential upside.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AMWL: